BCM
MDGL icon

Bayesian Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bayesian Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-491
Closed -$225K – 371
2025
Q3 		$225K Sell
491
-889
-64% -$332K 0.05% 442
2025
Q2 		$418K Buy
+1,380
New +$411K 0.07% 324
2025
Q1 		– Sell
-3,573
Closed -$1.1M – 817
2024
Q4 		$1.1M Buy
3,573
+2,071
+138% +$582K 0.13% 217
2024
Q3 		$319K Sell
1,502
-1,907
-56% -$488K 0.04% 465
2024
Q2 		$955K Buy
+3,409
New +$811K 0.11% 244
2023
Q3 		– Sell
-5,860
Closed -$1.35M – 864
2023
Q2 		$1.35M Buy
+5,860
New +$1.59M 0.15% 190
2023
Q1 		– Sell
-2,350
Closed -$682K – 972
2022
Q4 		$682K Buy
+2,350
New +$230K 0.1% 274

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's MDGL Position: Q4 2025 in Review

Bayesian Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 491 shares — an estimated $225K sold.

Bayesian Capital Management first reported a position in MDGL in Q4 2022 and held it in 7 quarters. The position peaked at $1.35M in Q2 2023. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Bayesian Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 491 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $225K.
  • Bayesian Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Bayesian Capital Management's Madrigal Pharmaceuticals position peaked at $1.35M in Q2 2023.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.